Jump to content

10,11-Seco-LSD

Edit links
From Wikipedia, the free encyclopedia

10,11-Seco-LSD
Clinical data
Other names"[0124]"; 9,10-Didehydro-N,N-diethyl-6-methyl-10,11-secoergoline-8β-carboxamide
Drug classPartial ergoline
ATC code
  • None
Identifiers
CAS Number
Chemical and physical data
3D model (JSmol)
  • O=C([C@@]1C=C[C@@]([H])(CC2=CN([H])C3=CC=CC=C23)N(C)C1)N(CC)CC
  • InChI=1S/C20H26N3O/c1-4-23(5-2)20(24)15-10-11-17(22(3)14-15)12-16-13-21-19-9-7-6-8-18(16)19/h6-11,13,17,21H,4-5,12,14H2,1-3H3/t17-/m0/s1
  • Key:CGFPZODXTFFRAH-KRWDZBQOSA-N

10,11-Seco-LSD is a partial lysergamide and cyclized tryptamine related to lysergic acid diethylamide (LSD).[1] It is the seco analogue of LSD in which the bond between the 10 and 11 positions of the ergoline ring system has been broken.[1] 10,11-Seco-LSD was described in a patent by David E. Olson and colleagues at Delix Therapeutics in 2021.[1] Its pharmacology was not described.[1]

LSD (left) and 10,11-seco-LSD (right) chemical structures.

See also

[edit]

References

[edit]
  1. ^ a b c d WO 2021076572, Olson DE, Dunlap LM, Wagner F, Chytil M, Powell NE, "Ergoline-like compounds for promoting neural plasticity", published 22 April 2021, assigned to Delix Therapeutics, Inc. and The Regents of the University of California 



Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=10,11-Seco-LSD&oldid=1344760636"